In conclusion, our **data** suggest that SYK could be a potential immunotherapy target antigen presented by DCs. These observations indicate that CTLs were largely activated by SYK overexpressed DCs with specific cytotoxicity on RB-Y79 cells. Moreover, we propose SYK as a candidate target for treatment of chemoresistant RB.